These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28883226)

  • 1. Rapid Globalization of Medical Device Clinical Development Programs in Japan　- The Case of Drug-Eluting Stents.
    Murakami M; Suzuki Y; Tominaga T
    Circ J; 2018 Feb; 82(3):636-643. PubMed ID: 28883226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiregional medical device development: regulatory perspective.
    Tamura A; Kutsumi H
    Clin J Gastroenterol; 2014 Apr; 7(2):108-16. PubMed ID: 26183624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New Medical Device Evaluation].
    Ikeda K
    Yakugaku Zasshi; 2016; 136(4):527-30. PubMed ID: 27040333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Price disparity of percutaneous coronary intervention devices in Japan and the United States in 2006.
    Yasunaga H; Ide H; Imamura T; Ohe K
    Circ J; 2007 Jul; 71(7):1128-30. PubMed ID: 17587722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global cardiovascular device innovation: Japan-USA synergies: Harmonization by Doing (HBD) program, a consortium of regulatory agencies, medical device industry, and academic institutions.
    Uchida T; Ikeno F; Ikeda K; Suzuki Y; Todaka K; Yokoi H; Thompson G; Krucoff M; Saito S;
    Circ J; 2013; 77(7):1714-8. PubMed ID: 23538483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary stents: looking forward.
    Garg S; Serruys PW
    J Am Coll Cardiol; 2010 Aug; 56(10 Suppl):S43-78. PubMed ID: 20797503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partnership Between Japan and the United States for Early Development of Pediatric Medical Devices　- Harmonization By Doing for Children.
    Takahashi S; Ibrahim N; Yasukochi S; Ringel R; Ing F; Tomita H; Sugiyama H; Yamagishi M; Forbes TJ; Kim SH; Ho M; Gillette N; Nakamura Y; Mineta K; Fearnot N; Dineen D; Vang E; Haskin R; Becker LAM; Sekiguchi K; Sakamoto K; Ruiz CE;
    Circ J; 2020 Apr; 84(5):786-791. PubMed ID: 32238666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials.
    Ushijima S; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2021 Jul; 35(4):253-260. PubMed ID: 34291425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Future Regulatory Science through a Global Product Development Strategy to Overcome the Device Lag].
    Tsuchii I
    Yakugaku Zasshi; 2016; 136(4):531-5. PubMed ID: 27040334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global Medical Device Clinical Trials Involving Both the United States and Japan: Key Considerations for Development, Regulatory Approval, and Conduct.
    Iwamoto S; Cavanaugh K; Malone M; Lottes A; Thatcher R; Kumar K; Rowland S; Fearnot N; Uchida T; Iwaishi C; Senshu K; Konishi R; Ikeda K; Suzuki Y; Ikeno F; Tamura A; Ho M; Ohashi M; Katayama H; Krucoff MW
    Cardiovasc Revasc Med; 2023 Jul; 52():67-74. PubMed ID: 36870799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan.
    Shirotani M; Kurokawa T; Chiba K
    J Clin Pharmacol; 2014 Jul; 54(7):753-64. PubMed ID: 24496890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing.
    Saito S; Nakamura S; Fujii K; Nakamura M; Isshiki T; Hirayama H; Kikuchi T; Fujita H; Nonogi H; Mitsudo K; Kimura T; Igarashi K; Saito K; Lansky AJ; Stone GW; Honda Y; Waseda K; Fitzgerald PJ; Sudhir K
    J Invasive Cardiol; 2012 Sep; 24(9):444-50. PubMed ID: 22954564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.
    Palmerini T; Benedetto U; Biondi-Zoccai G; Della Riva D; Bacchi-Reggiani L; Smits PC; Vlachojannis GJ; Jensen LO; Christiansen EH; Berencsi K; Valgimigli M; Orlandi C; Petrou M; Rapezzi C; Stone GW
    J Am Coll Cardiol; 2015 Jun; 65(23):2496-507. PubMed ID: 26065988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of mid-term clinical outcomes after treatment of ostial right coronary artery lesions with early and new generation drug-eluting stents: Insights from an international multicenter registry.
    Mitomo S; Jabbour RJ; Watanabe Y; Mangieri A; Ancona M; Regazzoli D; Tanaka A; Nakajima A; Naganuma T; Giannini F; Latib A; Nakamura S; Colombo A
    Int J Cardiol; 2018 Mar; 254():53-58. PubMed ID: 29407132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stent thrombosis with bioabsorbable polymer drug-eluting stents: insights from the Food and Drug Administration database.
    Khan AR; Tripathi A; Farid TA; Abaid B; Bhatt DL; Resar JR; Flaherty MP
    Coron Artery Dis; 2017 Nov; 28(7):564-569. PubMed ID: 28731889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
    JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design criteria for the ideal drug-eluting stent.
    Ako J; Bonneau HN; Honda Y; Fitzgerald PJ
    Am J Cardiol; 2007 Oct; 100(8B):3M-9M. PubMed ID: 17950830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective.
    Ando Y; Hamasaki T
    Pharm Stat; 2010; 9(3):190-200. PubMed ID: 20737442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.